Nektar Therapeutics (NKTR) Other Operating Expenses (2010 - 2024)

Nektar Therapeutics' Other Operating Expenses history runs 16 years deep, the most recent figure standing at -$43.3 million for Q2 2025.

• In Q2 2025, Other Operating Expenses rose 3.12% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$43.3 million (up 87.36% YoY), while the FY2024 annual figure was -$175.9 million, down 13432.46% from the prior year.
• Other Operating Expenses for Q2 2025 stood at -$43.3 million, up from -$50.5 million in the prior quarter.
• The five-year high for Other Operating Expenses was $103.2 million in Q1 2023, with the low at -$198.6 million in Q4 2024.
• The 5-year median for Other Operating Expenses is $5.3 million (2021), against an average of -$18.6 million.
• Peak annual rise in Other Operating Expenses reached 1840.85% in 2023, while the deepest fall reached 2556.73% in 2023.
• Nektar Therapeutics' Other Operating Expenses stood at $6.2 million in 2021, then gained by 1.14% to $6.2 million in 2022, then sank by 2556.73% to -$153.1 million in 2023, then decreased by 29.72% to -$198.6 million in 2024, then surged by 78.21% to -$43.3 million in 2025.
• Business Quant data shows NKTR's Other Operating Expenses at -$43.3 million in Q2 2025, -$50.5 million in Q1 2025, and -$198.6 million in Q4 2024.